Nonallergic Rhinitis Market Analysis

Nonallergic Rhinitis Market Overview

The nonallergic rhinitis market is projected to reach USD 11,183.14 Million by 2030 at 5.3% CAGR during the forecast period 2022-2030.The rising incidences of nonallergic rhinitis and the growing need for nonallergic rhinitis diagnosis and treatment are the primary drivers driving the global market growth.

Nonallergic rhinitis, also called vasomotor rhinitis, is a medical disorder characterized by a collection of symptoms that resemble nasal allergies and hayfever (allergic rhinitis) but are not caused by allergens. Postnasal drip, Runny nose, Sneezing, and Stuffy nose are some of the symptoms of nonallergic rhinitis. Because some individuals with nonallergic rhinitis may acquire allergies or asthma in the future, it is critical to treat the problem early on.

The market is growing due to several innovative medicines presently available on the market and various active research initiatives to develop breakthrough therapeutics and pharmaceuticals to treat illnesses. Also, important factors such as the rising incidence of nonallergic rhinitis and the increasing need to diagnose and treat disorders are fueling the global market forward.

Other factors driving market expansion include rising population, urbanization, and industrialization, all of which are fueled by better economic conditions, extending access to high-quality healthcare, and driving up healthcare spending. Furthermore, the market expansion is aided by the rising healthcare business as well as excellent immunology research.

Covid-19 Analysis

With the rise of the Covid-19 impact, many large-scale businesses and industries suffered, except healthcare and life support products. The lockdown and physical distancing protocols have affected millions of small and big business institutions alike. The non-allergenic rhinitis diagnosis & treatment market saw a slight downfall due to the lockdown and physical distancing.

However, the key companies have adopted measures to expand the distribution of nonallergenic rhinitis treatment and diagnosis equipment across the globe. Moreover, people are growing aware of nonallergenic rhinitis, and the price of pharmaceutical products is increasing. Hence, these factors are expected to boost the nonallergic rhinitis market value in the years to come.

Market Dynamics

Drivers

The rising incidences of nonallergic rhinitis and the growing need for nonallergic rhinitis diagnosis and treatment are the primary drivers driving the nonallergic rhinitis market growth. Other factors include rising population, urbanization, and industrialization, fueled by better economic conditions, extending access to high-quality healthcare, and driving up healthcare spending.

Opportunities

Due to multiple major and minor significant players, the nonallergenic rhinitis treatment & diagnosis market seems fragmented. These market participants attempt to acquire a competitive edge through strategic initiatives such as partnership, acquisition, expansion, cooperation, and product and technology launches. Significant efforts are being made in R&D to produce a treatment technique that is on a completely different level than its competitors.

Restraints

There are a few factors that may inhibit the nonallergic rhinitis market growth. Increased rivalry among leading companies in the market, which acts as a barrier to new entrants, limits the industry's expansion. 

Challenges

There are various concerns with the market that may challenge the key players of the nonallergic rhinitis market. This includes the cost of the diagnosis and treatment solutions. High treatment and maintenance costs for nonallergenic rhinitis and related illnesses and a lack of infrastructure in medium and low-income nations may limit the expansion of the market.

Cumulative Growth Analysis

The nonallergic rhinitis market value is expected to grow at a CAGR (Compound Annual Growth Rate) of about 5.3%. The rising incidences of nonallergic rhinitis and the growing need for nonallergic rhinitis diagnosis and treatment are the primary drivers driving the global market growth during the nonallergic rhinitis market forecast.

Value Chain Analysis

Although the exact origins of nonallergic rhinitis are unclear, environmental irritants are thought to be prevalent triggers. Nonallergic rhinitis therapy varies depending on severity; for mild instances, home treatment and avoiding triggers may suffice, however for more severe cases, medicines such as nasal antihistamines, oral decongestants, and over-the-counter (OTC) or prescription treatments are recommended.

The nonallergic rhinitis market share expansion is aided by the rising healthcare business and excellent immunology research. Market growth is likely to be supported during the study period by factors such as an increasing focus on developing novel treatments and an increase in the usage of non-steroidal anti-inflammatory drugs (NSAIDs). The market is expected to grow due to the rising demand for nasal sprays and over-the-counter medications and the availability of highly skilled medical experts committed to chronic illness research.

Segment Overview

The global market is classified into many segments such as diagnosis, treatment, and end-user. Listed below are the nonallergic rhinitis market segments:

By Diagnosis

• Physical Examination


• Imaging Test




• Nasal Endoscopy


• Computerized Tomography (CT) Scan




• Allergy Testing




• Skin test


• Blood test




• Others

By Treatment 

• Nasal sprays




• Antihistamine


• Anti-drip anticholinergic


• Saline


• Decongestants


• Corticosteroid




• NSAIDs


• Others

By End-user

• Hospitals & clinics


• Research centers


• Others

Regional Analysis

The regional division of the nonallergic rhinitis market analysis comprises North America, Europe, Asia Pacific, and the rest of the world. America leads the market because of the increased frequency of nonallergic rhinitis in the United States and the resulting growth in demand for innovative diagnostic and treatment services. Also, because of major industrial participants, North America is the largest market in the Americas. Furthermore, increased awareness of the morbidity associated with nonallergic rhinitis and the existence of important companies in the market affect market growth.

Europe is the second largest nonallergic rhinitis market. In Europe, there is a growing need for nasal sprays and considerable research and development operations for chronic illness treatment by clinical research and academic organizations. Due to a rise in the number of market participants manufacturing NSAIDs and the general expansion of the healthcare industry, Germany and France are the leading drivers of market growth.

The Asia Pacific is predicted to be the fastest-growing market, owing to an increase in the number of patients with nonallergic rhinitis and more knowledge of the diagnostic and treatment options. India, China, and Japan have all made significant contributions to the market's expansion. This rise can be linked to the rising demand for nasal sprays and over-the-counter drugs, as well as the availability of highly skilled medical experts committed to chronic illness research.

Because of the low frequency of nonallergic rhinitis and growing knowledge of allergic and nonallergic rhinitis therapy, the Middle East and Africa are also seeing consistent growth in the market. In the Middle East and Africa, the Middle East has the greatest market share regarding specialty medical services and rising healthcare spending.

Competitive Landscape

The non-allergenic rhinitis industry is dominated by a few companies that play a vital role in the market growth. These non-allergenic rhinitis diagnosis and treatment provider companies are called key companies of the market. They contribute to the largest share of the market profit.

The companies account for the market profits by adopting various nonallergic rhinitis market trends such as joint ventures, product launches, company expansions, and procurements. They provide innovative solutions for patients suffering from nonallergenic rhinitis.

Key Players

Below are the key companies that offer nonallergenic rhinitis diagnosis and treatment solutions in the global market, along with the location of their headquarters:

• Perrigo Company plc. (Ireland)


• Sanofi (France)


• Boehringer Ingelheim GmbH (Germany)


• Bayer (US)


• Novartis (US)


• Johnson & Johnson Consumer Inc. (US)


• GlaxoSmithKline (UK)


• Others

Recent Developments

• On 8th November 2018, AstraZeneca Plc. (UK), a worldwide pharmaceutical and biopharmaceutical firm has sold its rights to Covis Pharma (Switzerland) for USD 350 million for the asthma medicine Alvesco (ciclesonide), nasal sprays Omnaris, and Zetonna (ciclesonide).


• AstraZeneca stated that divesting sections of its portfolio was one of its strategic goals. It would allow the firm to focus resources on developing breakthrough new medications to meet unmet patient needs. Patients will continue to benefit from Alvesco, Omnaris, and Zetonna, which are used to treat nasal symptoms associated with seasonal allergic and nonallergic perennial rhinitis.

Report Overview

This report delivers all the information about the nonallergic rhinitis market size in the forecast period. It also contains different sections of the market analysis to help obtain detailed information such as opportunities, challenges, drivers, Covid-19 analysis, regional analysis, competitive landscape, and others. Moreover, all the information is collected from verified primary and secondary sources to provide the expected market outlook.

Geographically

• Europe


• Asia-Pacific


• North America


• Middle East & Africa


• Rest of the world